Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01528241 | Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET) | PHASE1 | COMPLETED | 42 | — | — | Aug 1, 2008 | May 1, 2010 | Dec 8, 2020 | 2 | United States |
Binding of \[11C\]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of \[11C\] ABP688. Specific times are recorded at the clinical site.
| Arm | Type | Description |
|---|---|---|
| ABP688 | EXPERIMENTAL | Elderly MDD patients and demography matched healthy volunteer |
| Name | Type | Description |
|---|---|---|
| ABP688 | DRUG | Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push. |
Inclusion Criteria: * Male and female subjects 55-80 (inclusive) * Subjects in good health At screening: * oral body temperature between 35-37.5C * systolic blood pressure: 90-140 mm Hg * diastolic blood pressure: 50-90 mm Hg * pulse rate: 40-90 bpm * Female subjects of child bearing potential mu...